PHARMASEAL, a new provider of clinical trial management and governance solutions, today announces the launch of a £1 million crowdfunding round with Seedrs.
The capital raised will enable the company to continue commercialisation and product development of the Engility® platform and support its mission to transform the management of clinical trials. Future clinical trials will require more flexible operating models, stronger collaboration across the clinical development supply chain and greater adoption of management technologies in the SME sector.
Founded in 2016 by a passionate team of industry leaders sharing a vision to create smarter technologies and innovative products for companies to improve their management of clinical trials, PHARMASEAL gained sector recognition when it launched its first commercial product in July 2019. Following three years of research and development and the release of two management products, PHARMASEAL is accelerating its business growth through the acquisition of new customers and the expansion of the Engility® platform with additional features.
“The timing is right for another round of capital to fuel our growth and help shape the future of clinical trials,” commented Daljit Cheema, Founder and CEO of PHARMASEAL. “We are excited to offer the opportunity to invest in our company and our success to date. Our Engility® cloud platform is specifically designed to help companies conduct and manage clinical trials more effectively and bring new medicines to market faster. Our mission is to develop intelligent clinical trial management technology for pharmaceutical, biotechnology, medical device and clinical research companies worldwide”.
Daljit added, “Clinical trials are critical to the discovery and development of new medicines; these medicines form an intrinsic component of our healthcare, which have benefited our families, our friends and society at large. We are passionate about reinventing the management of clinical trials. Our platform Engility®, simplifies the management, control and visibility of clinical trials”.
The PHARMASEAL crowdfunding pre-registration campaign is now live on Seedrs and can be seen here, where you can register your interest and be notified when the campaign goes live. Additionally, UK investors can benefit from tax relief under the Enterprise Investment Scheme (EIS).
PHARMASEAL’s integrated enterprise platform Engility® has been selected and licensed to help manage clinical trials for a leading US health outcomes and technology company, with several other opportunities in the pipeline. The company scooped its first industry award as Best Start-Up of the Year at Medilink East Midlands Business Awards 2019, in addition to launching its second major release.
This article was written by Medilink EM Member, PHARMASEAL.
